Skip to content

Twitter Linkedin Instagram

info@pharmaust.com+61 8 6161 7412

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: January 30, 2017

PharmAust receives $406K R&D rebate from ATO

News & Announcements 2017By PharmAust January 30, 2017

170130_PHARMAUST RECEIVES $406K R&D REBATE FROM ATO

Recent Articles

Intellectual Property Update
March 5, 2019
Appendix 4D and Financial Report
March 1, 2019
Top 20 Shareholders, March 1
March 1, 2019
Offer Document – Rights Issue
February 25, 2019

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust @PharmAust·

PharmAust is basking in the early success of Phase I clinical trials for its flagship anti-cancer drug Monepantel in dogs. https://t.co/Mv2qtDMfjE

Reply on Twitter Retweet on Twitter1 Like on Twitter1 Twitter

Copyright © 2019 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions